Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

INSULET CORPORATION

(PODD)
  Report
Delayed Quote. Delayed Nasdaq - 11/29 04:00:00 pm
295.87 USD   +0.16%
11/25Insulet to Present at Nasdaq's 45th Investor Conference
AQ
11/24Insulet to Present at Nasdaq's 45th Investor Conference
BU
11/15INSIDER SELL : Insulet
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Insulet : to Announce Third Quarter 2021 Financial Results on November 4, 2021

09/29/2021 | 04:02pm EST

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the third quarter of 2021 on November 4, 2021 after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time).

The link to the live call will be available on the Investor Relations section of the Company's website at investors.insulet.com, “Events and Presentations,” and will be archived for future replay. To participate in the live call via phone, please pre-register online here. You will then receive a telephone number and passcode required to enter the call.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, please visit: insulet.com and omnipod.com.


ę Business Wire 2021
All news about INSULET CORPORATION
11/25Insulet to Present at Nasdaq's 45th Investor Conference
AQ
11/24Insulet to Present at Nasdaq's 45th Investor Conference
BU
11/15INSIDER SELL : Insulet
MT
11/08Raymond James Adjusts Price Target on Insulet to $329 from $285, Keeps Outperform Ratin..
MT
11/08UBS Lifts Insulet's Price Target to $325 From $267 on Sales Estimates; Neutral Rating K..
MT
11/08Berenberg Bank Adjusts Insulet's Price Target to $295 From $277, Maintains Hold Rating
MT
11/05SVB Leerink Adjusts Price Target on Insulet to $350 from $300, Keeps Outperform Rating
MT
11/05INSULET CORP Management's Discussion and Analysis of Financial Condition and Results o..
AQ
11/04Insulet Reports Third Quarter 2021 Revenue Increase of 18% Year-Over-Year - Form 8-K
PU
11/04Insulet Posts Q3 EPS Gain Short of Street View as Revenue Rises, Lifts Low End of 2021 ..
MT
More news
Analyst Recommendations on INSULET CORPORATION
More recommendations
Financials (USD)
Sales 2021 1 092 M - -
Net income 2021 15,6 M - -
Net Debt 2021 347 M - -
P/E ratio 2021 1 258x
Yield 2021 -
Capitalization 20 372 M 20 372 M -
EV / Sales 2021 19,0x
EV / Sales 2022 16,1x
Nbr of Employees 1 900
Free-Float 99,5%
Chart INSULET CORPORATION
Duration : Period :
Insulet Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INSULET CORPORATION
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Last Close Price 295,39 $
Average target price 309,65 $
Spread / Average Target 4,83%
EPS Revisions
Managers and Directors
Shacey Petrovic President, Chief Executive Officer & Director
Wayde Dwight McMillan Chief Financial Officer, Treasurer & Executive VP
Timothy J. Scannell Independent Chairman
Trang Ly Senior Vice President & Medical Director
Charles Alpuche Chief Operations Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
INSULET CORPORATION15.55%20 372
ABBOTT LABORATORIES14.97%222 592
MEDTRONIC PLC-5.20%149 347
BECTON, DICKINSON AND COMPANY-2.05%69 611
HOYA CORPORATION25.86%59 428
DEXCOM, INC.60.11%57 374